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Robust Stimulation of Humoral and Cellular Immune Responses
following Vaccination with Antigen-Loaded -Glucan Particles
Haibin Huang,a Gary R. Ostroff,b Chrono K. Lee,a Charles A. Specht,a and Stuart M. Levitza
Department of Medicinea and Program in Molecular Medicine,b University of Massachusetts Medical School, Worcester, Massachusetts, USA
ABSTRACT -Glucan particles (GPs) are purified Saccharomyces cerevisiae cell walls treated so that they are primarily 1,3-D-
glucans and free of mannans and proteins. GPs are phagocytosed by dendritic cells (DCs) via the Dectin-1 receptor, and this in-
teraction stimulates proinflammatory cytokine secretion by DCs. As the hollow, porous GP structure allows for high antigen
loading, we hypothesized that antigen-loaded GPs could be exploited as a receptor-targeted vaccine delivery system. Ovalbumin
(OVA) was electrostatically complexed inside the hollow GP shells (GP-OVA). Incubation of C57BL/6J mouse bone marrow-
derived DCs with GP-OVA resulted in phagocytosis, upregulation of maturationmarkers, and rapid proteolysis of OVA. Com-
pared with free OVA, GP-OVAwas>100-fold more potent at stimulating the proliferation of OVA-reactive transgenic CD8
OT-I and CD4OT-II T cells, as measured by in vitro [3H]thymidine incorporation using DCs as antigen-presenting cells. Next,
immune responses in C57BL/6J mice following subcutaneous immunizations with GP-OVAwere compared with those in
C57BL/6J mice following subcutaneous immunizations with OVA absorbed onto the adjuvant alum (Alum/OVA). Vaccination
with GP-OVA stimulated substantially higher antigen-specific CD4 T-cell lymphoproliferative and enzyme-linked immuno-
spot (ELISPOT) responses than that with Alum/OVA. Moreover, the T-cell responses induced by GP-OVAwere Th1 biased (de-
termined by gamma interferon [IFN-] ELISPOT assay) and Th17 biased (determined by interleukin-17a [IL-17a] ELISPOT as-
say). Finally, both the GP-OVA and Alum/OVA formulations induced strong secretions of IgG1 subclass anti-OVA antibodies,
although only GP-OVA induced secretion of Th1-associated IgG2c antibodies. Thus, the GP-based vaccine platform combines
adjuvanticity and antigen delivery to induce strong humoral and Th1- and Th17-biased CD4 T-cell responses.
IMPORTANCE Most licensed vaccines work by promoting protective antibody responses. However, for many infectious diseases,
antibody-mediated protection appears to play a relatively minor role, and vaccination has met with limited success. While live-
attenuated organisms generally elicit T-cell responses, their use in vaccines is limited by the potential for causing disease. Thus,
there is an urgent need for new vaccine platforms that deliver antigens in such a manner as to promote strong T-cell-mediated
responses. Here we designed a novel vaccine platform consisting of yeast-derived -glucan particles (GPs) that combines antigen
delivery and adjuvant activity. GPs loaded with the model antigen ovalbumin (OVA) stimulated robust humoral and T-cell re-
sponses in mice. In addition, the cellular response was Th1 and Th17 biased. This work has implications for the design of vac-
cines that stimulate biased T-cell responses as well as for understanding how immunity to fungal pathogens develops.
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-Glucan particles (GPs) are purified Saccharomyces cerevisiae cell
walls treated so that they are85%1,3-D-glucan polymers, ~2%
chitin, and1% lipids and protein, with the rest beingmostly ash
and moisture (1). -Glucans are naturally found in fungi, algae,
plants, and some bacteria. -Glucans, especially 1,3-D-glucans,
are key constituents of the cell walls of fungal and major fungal
pathogen-associatedmolecular patterns (PAMPs) (2, 3). They are
recognized by the pattern recognition receptor Dectin-1, a C-type
lectinwhich has high levels of expression onphagocytes, including
dendritic cells (DCs), macrophages, and neutrophils (4, 5). It has
been previously demonstrated that GPs can be efficiently taken up
by mouse bone marrow-derived DCs (BMDCs) in vitro (6). In
addition, the hollow, porous GP structure allows for high antigen
loading (7, 8). This suggests that GPs have the potential to be
exploited as a targeted antigen delivery vehicle.
PAMPs have been extensively studied because of their impor-
tance in host defense against microbes. More recently, there has
been a growing recognition of the potential role of PAMPs in
vaccine development (9). PAMPsdeliver a “danger” signal toDCs,
resulting inDC activation and secretion of cytokines/chemokines,
migration, maturation, antigen presentation, and costimulatory
molecule expression. This, in turn, impacts B- and T-cell re-
sponses to antigens codelivered with PAMPs. Curdlan and yeast
glucan particles have been shown to have this type of adjuvant
activity (10, 11).
We hypothesized that antigen-loaded GPs could serve as a
RESEARCH ARTICLE
July/August 2010 Volume 1 Issue 3 e00164-10 mbio.asm.org 1
receptor-targeted vaccine delivery system that exploited the adju-
vanticity of 1,3-D-glucan. The model antigen ovalbumin (OVA)
was complexed in GPs and studied for its capacity to stimulate
immunologic responses inmice in vitro and in vivo.We found that
immunization with OVA complexed in GPs (GP-OVA) induced
robust Th1- and Th17-biased T-cell responses and strong anti-
body responses.
RESULTS
Proteolysis of antigens loaded into GPs.We previously demon-
strated that GPs are efficiently taken up by BMDCs in vitro (6). In
order to demonstrate that antigens encapsulated in GPs can be
efficiently proteolysed by DCs, we loaded GPs with DQ-OVA.
DQ-OVA consists of OVA that is heavily conjugated with
BODIPY FL, resulting in self-quenching. Upon proteolytic degra-
dation of DQ-OVA to single dye-labeled peptides, bright green
fluorescence is observed. Incubation of GP-DQ-OVA with
BMDCs resulted in the uptake of the particles and subsequent
proteolytic degradation of DQ-OVA (Fig. 1). This was evidenced
by progressively increased fluorescence over the time period stud-
ied by both epifluorescence microscopy and fluorescence-
activated cell sorting (FACS) analysis.
DC maturation. Optimal antigen presentation and subse-
quent CD4 T-cell responses require DC maturation, a process
that includes upregulation of costimulatory molecules and major
histocompatibility complex class II (MHC-II) (12). Incubation of
BMDCs with GP-OVA induced upregulation of two costimula-
tory molecules, CD40 and CD86, andMHC-II (Fig. 2). Lipopoly-
saccharide (LPS), a known DCmaturation stimulus, also upregu-
lated CD40, CD86, andMHC-II. The results suggest that GPs can
have adjuvant activity when used to immunize animals.
Antigen delivery activity of GP-OVA particles. In order to
demonstrate whether the antigens encapsulated in GPs can be
efficiently presented by BMDCs, we performed in vitroT-cell pro-
liferation assays, using OVA as the model antigen. CD8 T cells
obtained from “knock-in” transgenicOT-Imice (which recognize
the OVA peptide in the context of MHC-I) and CD4 T cells
obtained from OT-II mice (which recognize the OVA peptide in
the context of MHC-II) were stimulated with either free OVA or
GP-OVA, using BMDCs as antigen-presenting cells (APCs). At
concentrations from 0.03 to 0.5 g/ml, free OVA failed to stimu-
late proliferation of eitherOT-I orOT-II T cells (Fig. 3A andB). In
contrast, GP-OVA at those concentrations stimulated robust
OT-I and OT-II T-cell proliferation (Fig. 3A and B). In order to
achieve similar stimulation effects of GP-OVA, 100 times or
higher concentrations of free OVA were required (Fig. 3A and B).
These results demonstrate that antigens delivered in GPs were
efficiently processed and presented by DCs.
Evaluation of GPs as an antigen delivery and adjuvant sys-
tem. The in vitro T-cell proliferation and DC maturation data
suggest that GPs have the potential to serve as both an antigen
delivery system and an adjuvant system. Therefore, in the next set
FIG 1 Proteolysis of GP-DQ-OVA following uptake by BMDCs. GP-DQ-OVA particles (3:1 particle-to-BMDC ratio) were incubated with CD11c-purified day
8 BMDCs for the indicated times, washed, and examined by bright-field and epifluorescence microscopies (A) or collected and examined by FACS analysis (B).
Photomicrographs are representative of two experiments. Histograms are representative of three experiments.
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of experiments, the immune responses in mice following immu-
nization with GP-OVA were evaluated. Controls included OVA
delivered in alum and unimmunized mice that received
phosphate-buffered saline (PBS).
T-cell proliferation after immunization. Two weeks after the
last boost, CD4 and CD8 T cells were purified from lymph
nodes and spleens and restimulated with OVA (in the form of
either free OVA or GP-OVA) in an ex vivo T-cell proliferation
assay. The mitogen concanavalin A (ConA) served as a positive
control. CD4 T cells obtained from mice immunized with GP-
OVA proliferated in response to free OVA and GP-OVA at much
higher levels than those that had received OVA in alum or PBS
(Fig. 4). GPs alone (without OVA) did not stimulate T cells from
any of the groups to proliferate, thus demonstrating that the
CD4 T-cell lymphoproliferation was specifically in response to
OVA. Lymphoproliferation of CD8 T cells from all immuniza-
tion groups in response to stimulation with OVA was similar to
that of unstimulated controls. This was not because the lympho-
cytes were incapable of proliferation, as the CD8 T cells did pro-
liferate when stimulated with ConA (data not shown).
Skewing of Th responses.The ex vivoT-cell proliferation assay
showed that GP-OVA induced strong T-cell responses inmice. To
determine the Th bias of this response, gamma interferon (IFN-;
Th1 type cytokine), interleukin-4 (IL-4; Th2 cytokine), and IL-
17a (Th17 cytokine) enzyme-linked immunospot (ELISPOT) as-
says were performed using CD4 T cells obtained from immu-
nized mice. GP-OVA-immunized mice had considerably more
IFN- and IL-17a ELISPOTs than IL-4 following ex vivo stimula-
tion with OVA (Fig. 5). Consistent with the lymphoproliferation
data, mice receivingOVA in alum had a near background number
of spots. These data indicated that the CD4 T-cell responses fol-
lowing immunization with GP-OVA were biased toward Th1 and
Th17.
Antibody responses. The above-described results showed that
GP-OVA was a strong inducer of T-cell responses. Measurement
of the antibody response to vaccination is also important because
for many infections, antibodies mediate protection. In addition,
determination of relative IgG1 and IgG2c subclass titers can give
clues as to the polarization of Th responses, as IgG2c titers are
associated with Th1 responses (13). Serum samples were analyzed
for OVA-specific IgG1 and IgG2c by enzyme-linked immunosor-
bent assay (ELISA). Both classes of antibodies were demonstrated
after just one immunization with GP-OVA (Fig. 6), and their lev-
els were elevated after the second and third immunization. In
contrast, OVA in alum elicited only IgG1 antibodies. These data
are consistent with the Th1 skewing results observed by ELISPOT
assays.
DISCUSSION
DCs play central roles bridging innate and adaptive immunity and
are the primary antigen-presenting cells initializing adaptive im-
munity. Targeted antigen delivery to DCs can result in enhanced
antigen presentation by DCs. Both natural receptor ligands and
receptor-specific antibodies have been used for targeted antigen
FIG 2 DCmaturation stimulated by GP-OVA. DCs were left unstimulated (gray area) or stimulated with GP-OVA (10:1 particle-to-BMDC ratio; red line) or
LPS (1g/ml; green line). Surface expression of CD40, CD86, andMHC-II was analyzed by FACS.Data shown are representative histograms resulting from three
independent experiments.
FIG 3 Lymphocyte proliferation stimulated by free OVA compared to that stimulated by OVA complexed in GPs (GP-OVA). T cells (105 cells/well) purified
from the lymph nodes and spleens obtained from OT-I (CD8) (A) and OT-II (CD4) (B) mice were incubated for 4 days with mitomycin C-treated BMDCs
(104 cells/well) and free OVA or GP-OVA over the indicated OVA concentration range. For wells containing GP-OVA, 105 GP-OVA (containing 6, 10, 20, 50,
or 100 g OVA per 108 GPs) were added to yield the indicated concentration of OVA. [3H]thymidine was added 24 h before harvesting. Data are the means
SE from a representative experiment (out of three); for each experiment, each sample was tested in triplicate.
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delivery (14–18).GPs are naturally occurring ligands forDectin-1,
which is highly expressed on DCs. GPs are efficiently phagocy-
tosed by BMDCs in a Dectin-1-dependent manner in vitro. In
addition, engagement of GPs with Dectin-1 leads to proinflam-
matory cytokine production (6) and upregulation of costimula-
tory molecules on DCs, part of the process of DC maturation,
which is essential for antigen presentation and induction of adap-
tive immunity.
Mice vaccinated with GP-OVA had robust humoral and Th1/
Th17-skewed T-cell immune responses. The GP-based platform
combines targeted antigen delivery and adjuvant activity and has
several advantages compared to other targeting systems. First, the
antigens are complexed into GPs noncovalently through electro-
static interaction. This eliminates the requirement for a chemical
synthesis step whereby the antigen and targeting molecule are
chemically conjugated. Second, because GPs themselves serve as
adjuvants, the need for additional adjuvants is obviated.
Th1- and Th17-skewed cell-mediated immune responses ap-
pear to be important components of defenses against a wide range
of fungal pathogens, includingCryptococcus neoformans,Aspergil-
lus fumigatus, and Candida albicans (19–21). Recent studies sug-
gest stimulation via Dectin-1 primes Th17, Th1, and cytotoxic
T-cell responses (11, 22–25). Moreover, targeted delivery of anti-
gen by conjugation to anti-Dectin-1 antibodies induced CD4
and CD8 T-cell responses at doses that antigen alone failed to
produce a response (25). Taken together with the data presented
herein, these results demonstrate the potential for-glucan-based
antigen delivery systems to stimulate robust T-cell-mediated im-
mune responses.
We could not detect significant OVA-specific CD8 T-cell
proliferation in mice immunized with GP-OVA, OVA absorbed
onto the adjuvant alum (Alum/OVA), or PBS. GPs are thought to
be taken up by DCs via phagocytosis, following which fusion with
endolysosomal compartments occurs (6). Thus, OVAdelivered in
GPs would be expected to be preferentially presented by the
MHC-II pathway rather than cross-presented by theMHC-I path-
way (26–29). However, this explanation does not account for our
finding that GP-OVA can stimulate CD8 T cells obtained from
OT-I mice to proliferate ex vivo. It is possible that a low degree of
cross-presentationmay be sufficient to stimulate OT-I CD8 cells
to proliferate, given that these cells are already OVA responsive.
Alternatively, the capacity for BMDCs to cross-present OVA de-
livered via GPs may be significantly greater than that of the DC
populations that phagocytose GP-OVA in vivo. Strategies are be-
ing investigated to improve the cross-presentation of antigens de-
livered by GPs in order to enhance the CD8 response.
Elicitation of memory responses is essential if vaccines are to
confer long-lasting protection. Studies are under way to deter-
mine if delivery of antigen via the GP platform stimulates central
and effector memory responses, and if so, the skewing of those
responses. Recent studies with models of listeriosis suggest that
antigen-specific Th1 cells were much more likely to enter the
memory cell pool than Th17 cells (30). However, delivery of an-
tigen via Dectin-1 may prove more effective at eliciting long-lived
Th17 T cells, given the observation that circulating human blood
contains memory Th17 cells specific for fungal antigens (31–33).
In addition to T-cell responses, vigorous antibody responses
were observed following vaccination with GP-OVA. Detectable
titers occurred following the administration of the priming dose,
and the titers increased with each subsequent boost. In addition,
whereas mice that received OVA in alum mounted only an IgG1
response, mice vaccinated with GP-OVA had both IgG1 and
FIG 4 OVA-specific ex vivo lymphoproliferative responses in vaccinated
mice. CD4 T cells were purified from lymph nodes and spleens of wild-type
mice that received three injections of PBS (control), OVA admixed with alum
(Alum/OVA), or OVA complexed in GPs (GP-OVA). Mitomycin C-treated
BMDCs served as APCs. DCs and T cells were incubated for 4 day in the
presence of no stimulants (Neg), 5g/ml of ConA, 50g/mlOVA, empty GPs
(10:1 particle-to-BMDC ratio) or GP-OVA (10:1 particle-to-BMDC ratio;
containing 0.5 g/ml OVA [final concentration]). [3H]thymidine was added
24 h before harvesting. Results are the means  SE from a representative
experiment (out of three), with each sample tested in triplicate. *, P 0.0001,
comparing the indicated groups.
FIG 5 Skewing of Th responses following vaccination with GP-OVA. CD4 T cells purified from vaccinated mice were incubated with mitomycin C-treated
BMDCs as APCs, with 50g/mlOVA as the antigenic stimulus (OVA) orwithout stimulus (OVA). Results for IFN- and IL-4 are themeans SE from three
independent experiments, and results for IL-17a are the means  SE from two independent experiments, with 4 to 6 mice/group. *, P  0.05, comparing
GP-OVA to controls or Alum/OVA with (OVA) or without (OVA) stimulus. Note that the y axis scale differs among groups.
Huang et al.
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IgG2c responses. The latter subclass is associated with Th1 re-
sponses in the C57BL/6J mouse (13).
Data published by our group and others found undetectable
IL-12p70 cytokine production following in vitro stimulation of
BMDCs by -glucans (6, 11, 34). IL-12p70 is a pivotal cytokine,
guiding the differentiation of Th1 cells. Thus, the robust Th1 re-
sponses observed in vivo, following immunization with GP-OVA,
and in other studies using OVAmixed with the -glucan curdlan
(11) would seem paradoxical. We speculate that several factors
may contribute to this discrepancy. First, most of the in vitro stud-
ies used culturedBMDCs,whichmaynot be fully representative of
the heterogeneous DC populations that respond to -glucans in
vivo. Indeed, DC subsets vary greatly in their ability to process and
present antigens (35–37). Second, cytokine secretion by macro-
phages responding to -glucan stimulation could contribute to
the Th skewing. Third,-glucans are potent activators of the com-
plement pathway (38), and responses to opsonized GPs likely dif-
fer from those to unopsonized GPs.
A low incidence of adverse events is critical for the advance-
ment of vaccine candidates. -Glucan preparations derived from
fungi have a record of safety in both preclinical and human trials
(39–41). In addition, GPs are derived from S. cerevisiae, which is
regularly consumed by humans without ill effects. Although fur-
ther testing is needed, these findings encourage the clinical devel-
opment of GPs as a vaccine platform.
Finally, the structure of GPs permits loading of relatively large
amounts of not only antigens but also other molecules with po-
tential immunomodulatory activity, such as Toll-like receptor
(TLR) ligands, small interfering RNA (siRNA), and cytokines (7,
8). This potentially allowsmanipulation of themagnitude and the
qualitative nature of the vaccine response. For example, enhanced
cytokine responses are seen when Dectin-1 and TLRs are cooper-
atively stimulated (6, 34). Thus, addition of a TLR ligand to GPs
could lead to greater adjuvanticity. Similarly, siRNAs targeting
negative regulators of proinflammatory pathways could poten-
tially be added to the GP platform to inhibit the generation of
regulatory T cells (42). Future studies will test these possibilities
and determine the capacity of GPs loaded withmicrobial antigens
to induce protective responses.
MATERIALS AND METHODS
Chemicals and cell culture media. Chemical reagents were purchased
from Sigma-Aldrich (St. Louis, MO), unless stated otherwise. RPMI 1640
media were obtained from Invitrogen Life Technologies (Carlsbad, CA).
R10 medium consists of RPMI 1640 containing 10% fetal bovine serum
(FBS; Tissue Culture Biologicals, Tulare, CA), 100 U/ml penicillin,
100 g/ml streptomycin, 2 mM L-glutamine (Invitrogen), 0.5 g/ml am-
photericin B, and 55 M 2-mercaptoethanol (2-ME; Invitrogen).
Chicken OVA was purchased from Worthington Biochemical Corpora-
tion (Lakewood, NJ). Incubation of cells was performed at 37°C in hu-
midified air containing with 5% CO2.
Mice.Wild-type C57BL/6J mice were obtained from the Jackson Lab-
oratory (Bar Harbor, ME). Transgenic OT-I and OT-II mice (Jackson
Laboratory) were bred at the animal facility at the University of Massa-
chusetts Medical School. Mice were specific pathogen free. All animal
procedures were carried out under a protocol approved by the University
of Massachusetts Medical School Institutional Use and Care of Animals
Committee.
Mouse BMDCs. BMDCs were made as shown in previous studies,
with a slight alteration (43, 44). Briefly, bone marrow cells were isolated
from the tibiae and femurs of 8- to 12-week-oldmice and then cultured in
R10medium supplementedwith 10%conditionedmedium from themu-
rine granulocyte-macrophage colony-stimulating factor (GM-CSF)-
secreting J558L cell line. On days 3 and 6, fresh GM-CSF-supplemented
R10 medium was added. On day 8, nonadherent cells were harvested and
purified with CD11c magnetic beads (magnetic cell separation system;
Miltenyi Biotec, Auburn, CA), per the protocol supplied by the manufac-
turer. Positively selected BMDCs were washed with RPMI 1640 three
times, treated with 50 g/ml mitomycin C for 30 min at 37°C, and finally
washed three times with R10medium before used as APCs in lymphopro-
liferation and ELISPOT assays.
GPs. GPs were prepared from S. cerevisiae (Fleischmann’s baker’s
yeast) using a series of alkaline and acidic extraction steps as previously
described (1, 6, 8). Briefly, following centrifugation and washing in water,
S. cerevisiaewas subjected to two rounds of hot alkali extraction by heating
for 1 h at 90°C in 1 M NaOH. The particles were suspended in water at
pH 4.5, heated at 75°C for 1 h, and then successively washed with water
(three times), isopropanol (four times), and acetone (two times). GPs
were dried to yield a free-flowing light tan powder. To count the GPs or
GP vaccine formulations, a 10-g/ml suspension of particles in 0.9% sa-
line was lightly sonicated, counted using a hemocytometer, and then kept
in aliquots at20°C until use. One microgram of GPs contains approxi-
mately 5 105 particles.
GP-OVA. GPs containing complexed OVA (GP-OVA) were made as
previously described, with a slight modification (8). Briefly, 10 mg of dry
GPs were swollen with 50 l of various concentrations of OVA dissolved
in 0.9% saline for 2 h at 4°C to minimally hydrate the GPs, allowing OVA
diffusion into the hollow GP cavity. The samples were then frozen at
80°C and lyophilized. To maximize OVA incorporation into the GP
shells, the dry GP-OVA formulations were swollen, mixed with 50 l of
sterile water for 2 h at 4°C, and relyophilized. To trapOVA inside the GPs,
the dryGP-OVA formulationswere heated to 50°C and swollenwith 50l
of 25 mg/ml tRNA (derived from torula yeast, type VI) in 50 mM Tris-
HCl, pH 8, 2 mM EDTA, and 0.15MNaCl for 30 min, and then 500l of
FIG 6 Antibody subclass titers following immunizations. Mice were bled 2 weeks after each immunization, and antibody subclasses were measured by ELISA.
Data are themeans SE, with fivemice in each group. P 0.05 by one-way ANOVAwith Tukey’smultiple comparison test, comparingGP-OVAwith any other
group except for IgG1 after 2 or 3 immunizations.
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10 mg/ml tRNA was added for 1 h at 50°C to complete the complexation
reaction, trapping OVA inside the GPs. The suspension was centrifuged
and washed three times in 0.9% saline, and particles were resuspended in
70% ethanol for 30 min, washed three additional times in sterile 0.9%
saline, resuspended, counted, diluted to 5  108 particles/milliliter in
0.9% saline, and stored at20°C. To calculate the amount of OVA incor-
porated into the GPs, the unbound OVA protein in the saline washes was
measured by bicinchoninic acid (BCA) assay (Pierce, Rockford, IL)
against an OVA standard. In addition, fluorescein-labeled OVA was pre-
pared by reaction with fluorescein isothiocyanate (FITC) and used as a
fluorescent tracer to estimate OVA incorporated in the GP-OVA particles
and unbound in the saline washes. Typically, OVA incorporation was in
excess of 90%. DQ-OVA (Invitrogen) was loaded into GPs in an manner
identical to that of OVA, resulting in 100 g DQ-OVA per 108 GP-DQ-
OVA particles.
Proteolysis of GP-DQ-OVA by BMDCs. CD11c-purified day 8
BMDCs were adhered to the bottom of a 35-mm glass-bottom culture
dish (MatTek, Ashland, MA) (for microscopy) or to six-well plates (for
FACS analysis) by incubation at 37°C for 1 h. GP-DQ-OVA particles were
then added to cells at a ratio of 3 to 1 and incubated at 37°C for the
indicated times. BMDCs in glass-bottom dishes were washed, fixed, and
examined by bright-field and epifluorescence microscopies. BMDCs in
six-well plates were collected after Versene (Invitrogen) treatment,
washed, fixed, and examined by FACS analysis.
BMDCmaturation.CD11c-purified day 8 BMDCs (2 106 cells/well
in six-well plates) were incubated with medium only, GP-OVA (10:1
particle-to-BMDC ratio), or LPS (1 g/ml) for 24 h. Cells were collected
after Versene treatment, washed, stained with FITC-conjugated anti-
mouseCD40, CD86, orMHC-II antibodies (eBioscience, SanDiego, CA),
fixed, and examined by FACS analysis.
Purification of T-cell subsets. Single-cell suspensions of harvested
mouse spleens were obtained by grinding with a syringe plunger against a
70-mcell strainer (BD, Bedford,MA). Red blood cells (RBCs) were then
lysed using RBC lysis buffer (eBioscience). Single-cell suspensions of dis-
sected brachial, inguinal, andmesenteric lymphnodeswere accomplished
by grinding with a syringe plunger against sterile fine stainless steel wire
cloth mesh (Small Parts Inc., Miami Lakes, FL). CD4 and CD8 T cells
were then purified from combined lymph node cells and splenocytes us-
ing CD4 and CD8 T-cell isolation kits (Miltenyi Biotec), according to
the protocol supplied by the manufacturer.
T-cell proliferation assays. Purified T cells (105 cells/well) were incu-
bated with mitomycin C-treated BMDCs (104 cells/well) and the indi-
cated stimuli for 4 days in round-bottom 96-well plates in 200 l R10
medium. [3H]thymidine (1 Ci/well; PerkinElmer, Boston, MA) was
added for the last 24 h of incubation. Each condition was studied in trip-
licate. Cells were collected on filter paper (Wallac, Turku, Finland) using
a harvester (Tomtec, Hamden, CT), and [3H]thymidine incorporation
was measured with a beta counter (Wallac 1450 Microbeta).
Mice and immunization. For immunizations, groups of wild-type
C57BL/6J mice (8 to 10 weeks old; 4 to 6 mice per group) received 100 l
of sterile PBS (control), 50 g OVA in 50% Imject alum (Thermo Scien-
tific, Rockford, IL) (Alum/OVA), or 50 g OVA complexed in 5  107
GPs (GP-OVA) by subcutaneous injection over the abdomen. Mice were
immunized three times at 3-week intervals (except for one experiment in
which mice received four injections, with similar results) and euthanized
2 weeks after the last immunization, at which time spleens, lymph nodes,
and blood were harvested for the T-cell and antibody assays described
above and below. About 500 l of blood samples was collected by heart
puncture immediately after the mice were euthanized. Serum samples
were prepared from the blood samples after clotting at 37°C for 1 h and
stored at20°C until antibody titers were evaluated by ELISA. Addition-
ally, in one experiment, tail vein blood samples (100 to 200 l) also were
collected 2 weeks after the first and second immunizations.
ELISPOT assays. Mouse IFN-, IL-4, and IL-17a ELISPOT assays
were performed according to the manufacturer’s protocol (Mabtech,
Mariemont, OH), with slight modifications. Briefly, 96-well MultiScreen
HTS plates (Millipore, Billerica, MA) were used. Mouse IFN-, IL-4, and
IL-17a capture antibodies at 5g/ml were used to coat the plates. Purified
CD4 T cells (105 cells or 2.5 104 cells per well), mitomycin C-treated
BMDCs (104 cells/well), and stimulants were incubated at 37°C for 42 to
45 h. Plates were developed with BCIP (5-bromo-4-chloro-3-
indolylphosphate)-NBT (nitroblue tetrazolium) solution. The spots were
counted with an ImmunoSpot ELISPOT reader (Cellular Technology
Ltd., Shaker Heights, OH).
OVA-specific antibody ELISA. Serum samples obtained from immu-
nized mice were serially diluted starting at 1:40 and then progressively
diluted 2-fold. Round-bottom 96-well plates with high binding (Corning,
Corning, NY) were coated with 50l of 10g/ml OVA in 0.1MNaHCO3
overnight at 4°C, washed three times with PBS with 0.05% Tween 20,
blocked with 100l 10% FBS in PBS for 1 h at room temperature, washed
three times with PBS with 0.05% Tween 20, and incubated with 50 l
diluted mouse sera at room temperature for 2 h. Wells were then washed
five times with PBS with 0.05% Tween 20, and incubated with biotin-
conjugated rat anti-mouse IgG1 (1:500 dilution in 10% FBS in PBS) (BD
Biosciences, San Jose, CA) or biotin-conjugated rat anti-mouse IgG2c
(1:1,000 dilution in 10% FBS in PBS) (Jackson ImmunoResearch, West
Grove, PA) at room temperature for 1 h. Then, the plates were washed five
times with PBS-0.05%Tween 20, incubated with streptavidin-conjugated
horseradish peroxidase (1:250 dilution in 10% FBS in PBS) (eBioscience)
at room temperature for 1 h, washed five timeswith PBS-0.05%Tween 20,
and then developed with tetramethylbenzidine solution (eBioscience).
The optical density at 450 nm (OD450) was measured on a plate reader
(Molecular Devices, Sunnyvale, CA). Each serum dilution was tested in
duplicate, and the antibody titer was defined as the dilution factor just
above the inflection point.
Statistics. GraphPad Prism Software was used for preparation of fig-
ures and statistical analyses. Comparisons of groups were performed us-
ing a one-way analysis of variance (ANOVA) with the Tukey multiple
correction test. Significance was defined as P values of0.05.
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